Lysogene gets MHRA and Research Ethics Committee approvals for Gene Therapy Clinical Trial in the UK
PARIS: Lysogene, a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, has received MHRA and Research Ethics Committee approvals to initiate the gene therapy clinical trial in the United Kingdom with LYS-GM101 for the treatment of…